These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 960333)

  • 21. [Microstructure of the Urinary Tract Stone Formations (author's transl)].
    Bausch WM; Sorger G
    Urologe A; 1975 Jul; 14(4):161-3. PubMed ID: 1154563
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Medicinal teas in the prophylaxis of urinary calculus. Effect of solubitrat on the excretion of lithogenic and inhibitory substances (author's transl)].
    Hesse A; Strenge A; Bach D; Vahlensieck W
    MMW Munch Med Wochenschr; 1981 Mar; 123(13):521-4. PubMed ID: 6785581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Induction of urinary bladder urothelial cancers in the rabbit by dibutylnitrosamine with an artificial bladder calculus as cocarcinogen].
    Bornhof C; Wolfrath G; Giedl J
    Urologe A; 1989 Nov; 28(6):339-43. PubMed ID: 2603278
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of etidronate disodium (EHDP) on calcium oxalate renal stones induced by synthetic 1 alpha(OH) vitamin D3 and ethylene glycol in rats].
    Kawamura J; Nonomura M; Okada Y; Yoshida O; Takashima M; Itokawa Y
    Hinyokika Kiyo; 1985 May; 31(5):749-62. PubMed ID: 3931444
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Toward phosphate therapy of bladder stones].
    Hallwachs O; Vogelsang G; Röhl L
    Z Urol Nephrol; 1969 Jan; 62(1):29-35. PubMed ID: 4317815
    [No Abstract]   [Full Text] [Related]  

  • 26. Anthraquinone-2,6-disulfonic acid as a disease-modifying osteoarthritis drug: an in vitro and in vivo study.
    Savarino L; Fioravanti A; Leo G; Aloisi R; Mian M
    Clin Orthop Relat Res; 2007 Aug; 461():231-7. PubMed ID: 17806152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Experimental lithiasis in rats: the role of hydrochlorothiazide and antibiotics in its prevention].
    Glina S; Srougi M; Sakai A; Yassuda PH; Mies S; Raia S; de Góes GM
    Rev Paul Med; 1984; 102(5):189-91. PubMed ID: 6531577
    [No Abstract]   [Full Text] [Related]  

  • 28. Studies of bladder stone disease in Thailand. XVI. Effect of 4-hydroxy-L-proline and orthophosphate supplementations on urinary composition and crystalluria.
    Valyasevi A; Dhanamitta S; Van Reen R
    Am J Clin Nutr; 1973 Nov; 26(11):1207-11. PubMed ID: 4748180
    [No Abstract]   [Full Text] [Related]  

  • 29. [Analytical evaluation of urinary calculi mineral composition].
    Machoy P
    Ann Acad Med Stetin; 1995; 41():259-71. PubMed ID: 8615550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Incidence and risk factors for calculi formation in patients treated with augmentation cystoplasty or intestinal substitution].
    López Cubillana P; Gómez Gómez G; Ruiz Gómez JM; Prieto González A; Asensio Egea LJ; Rigabert Montiel M; Nicolás Torralba JA; Bañón Pérez V; Server Pastor G; Pérez Albacete M
    Arch Esp Urol; 1998 May; 51(4):347-52. PubMed ID: 9656556
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two validated HPLC methods for the quantification of alizarin and other anthraquinones in Rubia tinctorum cultivars.
    Derksen GC; Lelyveld GP; van Beek TA; Capelle A; de Groot AE
    Phytochem Anal; 2004; 15(6):397-406. PubMed ID: 15599964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Counteraction of oxalate induced nitrosative stress by supplementation of l-arginine, a potent antilithic agent.
    Pragasam V; Kalaiselvi P; Sumitra K; Srinivasan S; Varalakshmi P
    Clin Chim Acta; 2005 Apr; 354(1-2):159-66. PubMed ID: 15748613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Renal electrolyte changes by allopurinol. A contribution in the prophylaxis of oxalic acid stones (author's transl)].
    Garke P; Terhorst B
    Urologe A; 1974 Jul; 13(4 Pt A):166-7. PubMed ID: 4212796
    [No Abstract]   [Full Text] [Related]  

  • 34. Studies on bladder stone disease in Thailand. XV. Factors affecting the solubility of calcium oxalate.
    Chulkaratana S; Van Reen R; Valyasevi A
    Invest Urol; 1971 Nov; 9(3):246-50. PubMed ID: 5137334
    [No Abstract]   [Full Text] [Related]  

  • 35. [Urolithiasis].
    Staehler W; Völter D; Ziegler H; Braun WD
    Med Welt; 1974 Jan; 25(1):1-7. PubMed ID: 4589864
    [No Abstract]   [Full Text] [Related]  

  • 36. Proceedings: Metabolic aspects of urinary calculi in Wellington.
    Morrison RB
    Br J Urol; 1974 Feb; 46(1):177-8. PubMed ID: 4816281
    [No Abstract]   [Full Text] [Related]  

  • 37. [Morphology and genesis of the centers in urinary calculi].
    Kolpakow IS
    Z Urol Nephrol; 1971 Sep; 64(9):641-7. PubMed ID: 5158141
    [No Abstract]   [Full Text] [Related]  

  • 38. Modification of N-Methyl-N-Nitrosourea initiated bladder carcinogenesis in Wistar rats by terephthalic acid.
    Cui L; Shi Y; Dai G; Pan H; Chen J; Song L; Wang S; Chang HC; Sheng H; Wang X
    Toxicol Appl Pharmacol; 2006 Jan; 210(1-2):24-31. PubMed ID: 16045953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Attenuation of oxalate-induced nephrotoxicity by eicosapentaenoate-lipoate (EPA-LA) derivative in experimental rat model.
    Lenin M; Thiagarajan A; Nagaraj M; Varalakshmi P
    Prostaglandins Leukot Essent Fatty Acids; 2001; 65(5-6):265-70. PubMed ID: 11993719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of tetracycline on calcium oxalate calculi: in vivo and in vitro studies.
    Selikowitz SM; Olsson CA
    Invest Urol; 1976 Sep; 14(2):124-7. PubMed ID: 972004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.